RT @synovialjoints: New in AS. Upadacitinib 15mg od was significantly more effective than placebo over 14 weeks in AS bD
Tweet Content
New in AS. Upadacitinib 15mg od was significantly more effective than placebo over 14 weeks in AS bDMARD-IR (ASAS40 45% vs 18% and the onset of effect seen by week 4), no new safety risks identified in the SELECT-AXIS 2 study by Van de Heijde et al #EULAR2022 @RheumNow POS0306 https://t.co/LCQBf38GWe
Show on Archive Page
On
Display in Search Results
On
PDQ
Off